Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer

Man-Tzu Wang; Nicole Fer; Jacqueline Galeas; Eric A. Collisson; Sung Eun Kim; Jeremy Sharib; Frank McCormick

doi:10.1038/s41467-019-11044-9

Nature Communications (Jul 2019)

Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer

Man-Tzu Wang,
Nicole Fer,
Jacqueline Galeas,
Eric A. Collisson,
Sung Eun Kim,
Jeremy Sharib,
Frank McCormick

Affiliations

Man-Tzu Wang: Tumor Microenvironment Center, UPMC Hillman Cancer Center; Department of Pharmacology and Chemical Biology, University of Pittsburgh
Nicole Fer: NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research
Jacqueline Galeas: Helen Diller Family Comprehensive Cancer Center, University of California
Eric A. Collisson: Helen Diller Family Comprehensive Cancer Center, University of California
Sung Eun Kim: Helen Diller Family Comprehensive Cancer Center, University of California
Jeremy Sharib: Department of Surgery, University of California
Frank McCormick: Helen Diller Family Comprehensive Cancer Center, University of California

DOI: https://doi.org/10.1038/s41467-019-11044-9
Journal volume & issue: Vol. 10, no. 1
pp. 1 – 10

Abstract

Read online

KRAS mutations are frequent in pancreatic ductal adenocarcinoma, leading to bad prognosis and resistance to targeted therapies. Here, the authors show that LIF expression is specifically induced by KRAS and constitutes a potential target to treat these KRAS-mutated cancers.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal